Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford South University Medical Center — Fargo, North Dakota
- Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Medical Center Fargo — Fargo, North Dakota
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Sanford South University Medical Center — Fargo, North Dakota
- Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in North Dakota: - Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC)…
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in North Dakota: - Research Site — Grand Forks, North Dakota
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in North Dakota: - Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0063) — Fargo, North Dakota
- Altru Health System ( Site 0040) — Grand Forks, North Dakota
Phase 3 Recruiting Industry
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as Fir…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06646276
Sites in North Dakota: - Sanford Medical Center — Bismarck, North Dakota
- Local Institution - 0010 — Fargo, North Dakota
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immun…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06731907
Sites in North Dakota: - Sanford Fargo Medical Center ( Site 0039) — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this st…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07252739
Sites in North Dakota: - Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota
Phase 2 Recruiting Academic/Other
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (adv…
Sponsor: Mayo Clinic
NCT ID: NCT05969860
Sites in North Dakota: - Altru Cancer Center — Grand Forks, North Dakota
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford South University Medical Center — Fargo, North Dakota
- Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Medical Center Fargo — Fargo, North Dakota
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in North Dakota: - Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in North Dakota: - Massive Bio SYNERGY-AI site — Fargo, North Dakota
Recruiting Academic/Other
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…
Sponsor: Addario Lung Cancer Medical Institute
NCT ID: NCT06486428
Sites in North Dakota: - Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, North Dakota
Recruiting Industry
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this m…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165798
Sites in North Dakota: - Sanford Fargo Medical Center ( Site 0039) — Fargo, North Dakota
NA Recruiting Academic/Other
Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to te…
Sponsor: University of North Dakota
NCT ID: NCT07591389
Sites in North Dakota: - University of North Dakota Center for Family Medicine, Bismarck Clinic — Bismarck, North Dakota
- University of North Dakota Center for Family Medicine, Minot Clinic — Minot, North Dakota